Patents by Inventor Mara Parzinger

Mara Parzinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240317780
    Abstract: Provided are novel SST receptor ligand compounds suitable for the imaging and/or the treatment of neuroendocrine tumors. These SST receptor ligand compounds are comprised of a SST binding motif, a silicon-fluoride acceptor group which can be labeled with 18F by isotopic exchange of 19F by 18F or which is labeled with 18F, a chelating group suitable for forming a chelate with a radioactive or non-radioactive cation, and a hydrophilic amino acid unit or a sequence of such units.
    Type: Application
    Filed: May 12, 2022
    Publication date: September 26, 2024
    Inventors: Hans-Jürgen Wester, Mara Parzinger, Markus Frederik Fahnauer
  • Publication number: 20230122957
    Abstract: The present invention relates to compounds which bind and/or inhibit prostate-specific membrane antigen (PSMA) comprising at least one group electron dense substituent (EDS), and at least one moiety which is amenable to radiolabeling; and therapeutic and diagnostic uses thereof.
    Type: Application
    Filed: July 15, 2022
    Publication date: April 20, 2023
    Inventors: Hans-Jürgen Wester, Alexander Schmidt, Mara Parzinger
  • Patent number: 11497819
    Abstract: The present invention relates to compounds which bind and/or inhibit prostate-specific membrane antigen (PSMA) comprising at least one group electron dense substituent (EDS), and at least one moiety which is amenable to radiolabeling; and therapeutic and diagnostic uses thereof.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: November 15, 2022
    Assignee: Technische Universität München
    Inventors: Hans-Jurgen Wester, Alexander Schmidt, Mara Parzinger
  • Publication number: 20200297876
    Abstract: The present invention relates to compounds which bind and/or inhibit prostate-specific membrane antigen (PSMA) comprising at least one group electron dense substituent (EDS), and at least one moiety which is amenable to radiolabeling; and therapeutic and diagnostic uses thereof.
    Type: Application
    Filed: December 11, 2018
    Publication date: September 24, 2020
    Inventors: Hans-Jürgen Wester, Alexander Schmidt, Mara Parzinger